ライフサイエンスコーパス: neck tumor

1 several weeks for locally advanced head and neck tumors).

2 ally advanced, and 83.2% had pancreatic head/neck tumors.

3 es compared with smoking-associated head and neck tumors.

4 ity is deregulated in certain human head and neck tumors.

5 reatment of haemorrhage in advanced head and neck tumors.

6 a large panel of breast, lung, and head and neck tumors.

7 terations were identified in 74% of head and neck tumors.

8 ay inhibit the angiogenic switch in head and neck tumors.

9 al cells adjacent to colorectal and head and neck tumors.

10 utic used to combat various brain, head, and neck tumors.

11 resonance energy transfer (FRET) in head and neck tumors.

12 uman squamous cell carcinoma of the head and neck tumors.

13 reported to show high LOH rates in head and neck tumors.

14 A205 murine fibrosarcomas and human head and neck tumors.

15 iants that appeared in the lung and head and neck tumors.

16 nmodulation of Bcl-xL expression in head and neck tumors.

17 rouracil in the treatment of breast and head-neck tumors.

18 tation events in breast, liver, and head and neck tumors.

19 he JCI, Nambiar et al. used patient head and neck tumors and a mouse model system to investigate the

20 ical experience in 18 patients with head and neck tumors and arteriovenous malformations.

21 IM-19, we screened a set of primary head and neck tumors and identified three somatic mutations in GR

22 l in the management of unresectable head and neck tumors and is safe and well tolerated.

23 Separate IRRs for head/neck tumors and torso/leg tumors were compared (IRR rati

24 in the p53 gene from Wilms' tumor, head and neck tumor, and colorectal tumor.

25 Survivors of a CNS tumor, head and neck tumor, and leukemia are particularly at risk of hos

26 f age, 9%, 6%, and 5% of CNS tumor, head and neck tumor, and leukemia survivors, respectively, had be

27 rd to work-up, management of the primary and neck tumors, and adjuvant therapy.

28 Four patients had head and neck tumors, and two had uterine cervix cancers.

29 s (PTK/ZK) on the initial stages of head and neck tumor angiogenesis.

30 ely activated in both primary human head and neck tumors as well as in normal mucosa from these cance

31 The treatment volumes for head and neck tumors as well as parotid glands can be well-define

32 bogen (95% O2, 5% CO2) in mice with head and neck tumors before (n = 11) and after (n = 9) treatment

33 We found that 9 of 10 head and neck tumor biopsies contained a subpopulation of cells t

34 e, lung cancer, melanoma, lymphoma, head and neck tumors, brain tumors, esophageal cancer, and colore

35 e early after treatment in squamous head and neck tumors can be adequately characterized with SUV obt

36 In vitro, PTK/ZK blocked head and neck tumor cell (OSCC3 or UM-SCC-17B)-induced Bcl-2 and

37 Head and neck tumor cells treated with radiation have significant

38 tant Hs578t breast tumor cells, HN6 head and neck tumor cells, and H358 non-small cell lung cancer ce

39 uisition of stem-like properties by head and neck tumor cells.

40 popharynx), and primary cultures of head and neck tumor cells.

41 s have established that a subset of head and neck tumors contains human papillomavirus (HPV) sequence

42 Using the 2021 HEad and neCK TumOR dataset for development and an external datas

43 Biopsy of a neck tumor demonstrated tumor-stage MF,with no evidence

44 ude mice bearing subcutaneous human head and neck tumors (FaDu) and human colorectal tumors (HT29) af

45 mediated autophagy is required for head and neck tumor growth in mice.

46 transfected with IL-13Ralpha2 chain head and neck tumor implanted s.c. in nude mice.

47 ary effect of treatment for CNS and head-and-neck tumors in children.

48 with advanced, treatment-resistant head and neck tumors, including squamous cell carcinoma (HNSCC),

49 with advanced, treatment-resistant head and neck tumors, including squamous cell carcinoma (HNSCC),

50 5 genes, which divide patients with head and neck tumors into two clinically distinct subgroups based

51 e available economic literature for head and neck tumors is limited; it is often compromised by the u

52 ect one of the neck muscles and present as a neck tumor, it can be misdiagnosed as the clinical, radi

53 ation of PTK/ZK decreased xenograft head and neck tumor microvessel density, and inhibited Bcl-2 and

54 ed in 44 patients with a variety of head and neck tumors or aneurysms.

55 ghly metastatic compared with other head and neck tumors, perhaps because of its viral link.

56 PET can detect head and neck tumor recurrence when it may be undetectable by oth

57 ory of nonmelanoma skin cancer, and head and neck tumors relative to other primary sites.

58 words: MRI Contrast Agent, MRI, Breast, Head/Neck, Tumor Response, Experimental Investigations, Brain

59 Expression analysis in primary head and neck tumor samples indicates that mir-210 may serve as a

60 95% confidence interval, 4.3-5.0), head and neck tumors (SHR=2.6, 95% confidence interval, 2.2-3.1),

61 Head and neck tumor site and tumor thickness are predictors of a

62 Despite the multiple head and neck tumor subsites and the variety of treatments, we fo

63 isks =7 versus 3), especially among head and neck tumor survivors (absolute excess risks =30 versus 1

64 eas at any age, every year, 0.2% of head and neck tumor survivors were hospitalized for a cerebral in

65 For head and neck tumor survivors, this excess risk remains high acro

66 We report a 29 year old female patient with neck tumor suspected to be a sarcoma who underwent full

67 or in a whole-body protocol for non-head and neck tumors, T2w PET/MR imaging may be sufficient for co

68 US and has been approved for use in head and neck tumor therapy in China, demonstrating that Ad conta

69 injury is a major adverse event in head and neck tumor treatment, influencing the quality of life fo

70 We tested 30 patients with primary head and neck tumors using methylation-specific PCR searching for

71 in 10 patients with concave-shaped head and neck tumors was performed by using tomotherapy and step-

72 Head and neck tumors were independently associated with a higher

73 For fast-growing head and neck tumors with a 2-month treatment delay, there was an

74 ntly observed in lung, bladder, and head and neck tumors with intact DNA mismatch repair.

75 In a cohort of head and neck tumors with low mutation burden, minimal immune inf

76 rived from cervix, vulvar, ovarian, and head/neck tumors with similar efficiencies to that of 9-c-RA

77 Moreover, head and neck tumors xenografted in macrophage-depleted nude mice